BioCatalyst

disitamab vedotin, pembrolizumab — catalyst calendar

1 verified catalyst event(s) referencing disitamab vedotin, pembrolizumab, each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12-11
in 3mo
ESTIMATED
 READOUT
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer Th
Phase 2 · Urothelial Carcinoma
 Seagen, a wholly owned subsidiary disitamab vedotin, pembrolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.